Cargando…

Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen–Antibody Interactions in Convalescent Plasma Therapy

Originating in China during December 2019, the novel corona-virus, SARS-CoV-2, has created mayhem worldwide in a very short time. The outbreak has been so rapid and widespread that the only option to treat the patients was administering drugs already available in the market like chloroquine/hydroxyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Nimisha, Kashyap, Jyoti, Verma, Deepti, Tyagi, Rakesh K., Prabhakar, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340772/
http://dx.doi.org/10.1007/s41403-020-00148-0
_version_ 1783555096112529408
author Roy, Nimisha
Kashyap, Jyoti
Verma, Deepti
Tyagi, Rakesh K.
Prabhakar, Amit
author_facet Roy, Nimisha
Kashyap, Jyoti
Verma, Deepti
Tyagi, Rakesh K.
Prabhakar, Amit
author_sort Roy, Nimisha
collection PubMed
description Originating in China during December 2019, the novel corona-virus, SARS-CoV-2, has created mayhem worldwide in a very short time. The outbreak has been so rapid and widespread that the only option to treat the patients was administering drugs already available in the market like chloroquine/hydroxychloroquine (an antimalarial drug) and remedesivir. A large number of patients have been cured but the attribution to survival by these drugs has been controversial. Till date, we do not have any specific drug or vaccine available for COVID-19 and the pandemic seems to be far from over. To handle the current challenges posed by the outbreak effectively, we need to employ innovative interdisciplinary approaches. Organ-on-chip (OOC), particularly lung-on-chip, is one such approach which combines the potential of microfluidics, cell culture and molecular biology into a single miniaturised platform. The device is realized to be capable of simulating in-vivo physiological responses of an organ. In the current study, an OOC, which is a multichannel 3D cell culture microfluidic device, is made via soft lithography technique, using polydimethylsiloxane-polymer and diverse polymeric porous/semipermeable membranes. Several polymer membranes i.e. PDMS, polyvinylidene fluoride (PVDF), nitrocellulose, polyester etc., integrated into the microdevices, were efficiently explored to realize their better cell-adhesion and viability property. We also propose for the application of a simple, smart and cost-effective lung-on-chip platform to study the SARS-CoV-2 pathogenesis in humans, drug toxicity testing and provide insights into antigen–antibody interactions. This platform will enable us to study multiple phenomena at a micro-level generating more reliable data and a better understanding of the underlying mechanisms of SARS-CoV-2 infection and pathogenesis.
format Online
Article
Text
id pubmed-7340772
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-73407722020-07-08 Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen–Antibody Interactions in Convalescent Plasma Therapy Roy, Nimisha Kashyap, Jyoti Verma, Deepti Tyagi, Rakesh K. Prabhakar, Amit Trans Indian Natl. Acad. Eng. Original Article Originating in China during December 2019, the novel corona-virus, SARS-CoV-2, has created mayhem worldwide in a very short time. The outbreak has been so rapid and widespread that the only option to treat the patients was administering drugs already available in the market like chloroquine/hydroxychloroquine (an antimalarial drug) and remedesivir. A large number of patients have been cured but the attribution to survival by these drugs has been controversial. Till date, we do not have any specific drug or vaccine available for COVID-19 and the pandemic seems to be far from over. To handle the current challenges posed by the outbreak effectively, we need to employ innovative interdisciplinary approaches. Organ-on-chip (OOC), particularly lung-on-chip, is one such approach which combines the potential of microfluidics, cell culture and molecular biology into a single miniaturised platform. The device is realized to be capable of simulating in-vivo physiological responses of an organ. In the current study, an OOC, which is a multichannel 3D cell culture microfluidic device, is made via soft lithography technique, using polydimethylsiloxane-polymer and diverse polymeric porous/semipermeable membranes. Several polymer membranes i.e. PDMS, polyvinylidene fluoride (PVDF), nitrocellulose, polyester etc., integrated into the microdevices, were efficiently explored to realize their better cell-adhesion and viability property. We also propose for the application of a simple, smart and cost-effective lung-on-chip platform to study the SARS-CoV-2 pathogenesis in humans, drug toxicity testing and provide insights into antigen–antibody interactions. This platform will enable us to study multiple phenomena at a micro-level generating more reliable data and a better understanding of the underlying mechanisms of SARS-CoV-2 infection and pathogenesis. Springer Singapore 2020-07-08 2020 /pmc/articles/PMC7340772/ http://dx.doi.org/10.1007/s41403-020-00148-0 Text en © Indian National Academy of Engineering 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Roy, Nimisha
Kashyap, Jyoti
Verma, Deepti
Tyagi, Rakesh K.
Prabhakar, Amit
Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen–Antibody Interactions in Convalescent Plasma Therapy
title Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen–Antibody Interactions in Convalescent Plasma Therapy
title_full Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen–Antibody Interactions in Convalescent Plasma Therapy
title_fullStr Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen–Antibody Interactions in Convalescent Plasma Therapy
title_full_unstemmed Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen–Antibody Interactions in Convalescent Plasma Therapy
title_short Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen–Antibody Interactions in Convalescent Plasma Therapy
title_sort prototype of a smart microfluidic platform for the evaluation of sars-cov-2 pathogenesis, along with estimation of the effectiveness of potential drug candidates and antigen–antibody interactions in convalescent plasma therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340772/
http://dx.doi.org/10.1007/s41403-020-00148-0
work_keys_str_mv AT roynimisha prototypeofasmartmicrofluidicplatformfortheevaluationofsarscov2pathogenesisalongwithestimationoftheeffectivenessofpotentialdrugcandidatesandantigenantibodyinteractionsinconvalescentplasmatherapy
AT kashyapjyoti prototypeofasmartmicrofluidicplatformfortheevaluationofsarscov2pathogenesisalongwithestimationoftheeffectivenessofpotentialdrugcandidatesandantigenantibodyinteractionsinconvalescentplasmatherapy
AT vermadeepti prototypeofasmartmicrofluidicplatformfortheevaluationofsarscov2pathogenesisalongwithestimationoftheeffectivenessofpotentialdrugcandidatesandantigenantibodyinteractionsinconvalescentplasmatherapy
AT tyagirakeshk prototypeofasmartmicrofluidicplatformfortheevaluationofsarscov2pathogenesisalongwithestimationoftheeffectivenessofpotentialdrugcandidatesandantigenantibodyinteractionsinconvalescentplasmatherapy
AT prabhakaramit prototypeofasmartmicrofluidicplatformfortheevaluationofsarscov2pathogenesisalongwithestimationoftheeffectivenessofpotentialdrugcandidatesandantigenantibodyinteractionsinconvalescentplasmatherapy